Judy Visits 2 - 3: A 77-year-old woman with age-related macular degeneration


Judy Visits 2 - 3: A 77-year-old woman with age-related macular degeneration

Topic: Ophthalmology
Relevant Terms: Age-related Macular Degeneration, Macular Disease, Ocular Disease, Cataracts
Primary Audience: Ophthalmologist; optometrists; retina specialists; and other eye care professionals
Launch Date: 08-Aug-13
Credits: 0.75 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Age-related Macular Degeneration: Seeing the Way Into the Future

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Identify risk factors associated with AMD in order to increase understanding the burden of the disease.
  2. Individualize treatment plans for patients with AMD in order to improve long-term management.
  3. Compare and contrast the current and potential future treatment of patients with AMD.


    William F. Mieler, MD
    Director, Ocular Oncology
    Professor and Vice-Chairman
    The Department of Ophthalmology and Visual Sciences
    The University of Illinois at Chicago
    Center for Advanced Medicine
    Chicago, IL
    Neil M. Bressler, MD
    Chief, Retina Division of The Wilmer Eye Institute
    The James P. Gills Professor of Ophthalmology
    Johns Hopkins University School of Medicine
    Baltimore, MD
    Peter K. Kaiser, MD
    Chaney endowed Chair in Ophthalmology Research
    Professor of Ophthalmology
    Cleveland Clinic
    Lerner College of Medicine
    Vitreonretinal Department
    Cole Eye Institute
    Cleveland, OH
    Age-related macular degeneration (AMD) is a common eye condition among people 50 years of age and older. It gradually destroys the macula, the part of the eye that provides sharp, central vision needed for seeing objects clearly.1 AMD is the leading cause of irreversible blindness in people ≥50 years of age in the developed world. It increases with age, and more than 8 million Americans have it.2 Approximately 5% of people >50 years old have signs of AMD, and the overall prevalence is projected to increase by >50% by the year 2020.
    There are two types of AMD: dry and wet. Dry AMD is the most common form; it occurs in about 90% of the people with the condition.1 Dry AMD occurs when the light-sensitive cells in the macula gradually break down, leading to blurred central vision in the affected eye. As it progresses, patients may see a blurred spot in the center of their vision (geographic atrophy). Over time, central vision in the affected eye can be lost as less of the macula operates correctly.1 Wet AMD affects the other 10% of people with AMD. However, this type is more severe than the dry form; it occurs when blood vessels behind the retina start to grow under the macula. These new blood vessels can be fragile and leak blood and fluid, which cause the macula to swell, resulting in damage. While loss of central vision can occur quickly, eye care professionals can slow down or stop the progression of wet AMD if it is detected before severe vision loss occurs.1

    Now that people are living longer the prevalence of AMD, as mentioned, is likely to increase.3 Early detection and prompt referral to a retina specialist may potentially reduce the high risk of severe vision loss.4 Unfortunately, there are several gaps in the detection and management of AMD, including misconceptions surrounding clinician perceptions of how AMD affects patients, diagnostic and treatment challenges, and perceived lack of education in the area of AMD. Our program aims to address these and other gaps associated with AMD.

    1. Facts About Age-Related Macular Degeneration. 2012; http://www.nei.nih.gov/health/maculardegen/armd_facts.asp - 1. Accessed May 8, 2012.
    2. Koby M. Macular Degeneration. Philadelphia: Mosby Elsevier; 2011.
    3. Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes. 2006;4:97.
    4. Sickenberg M. Early detection, diagnosis and management of choroidal neovascularization in age-related macular degeneration: the role of ophthalmologists. Ophthalmologica. Jul-Aug 2001;215(4):247-253.

    CME Advisory Committee
    Course Director/Course Reviewer
    Katherine Galluzzi, DO, CMD, FACOFP dist.
    Professor and Chairperson, Department of Geriatrics
    Philadelphia College of Osteopathic Medicine
    Attending Physician, Family Medicine
    Tenet Roxborough Memorial Hospital
    Philadelphia, PA
    Planning Committee
    Kelly Kraines
    Director of CME/CE
    Med Learning Group
    Christopher Cahill
    Associate Director, Planning and Projects
    Med Learning Group
    Joshua Kilbridge
    Kilbridge Associates
    Healthcare Communications
    In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
    William F. Mieler, MD
    Disclosure:  Dr. Mieler receives Consulting Fees from Alcon, Allergan and Genentech/Roche.
    Peter K. Kaiser, MD
    Disclosure: Dr. Kaiser receives Consulting Fees from Alcon, AcrticDx, Bausch and Lomb, Bayer, Novartis, Ophthotec, Oraya, and Regeneron.  Dr. Kaiser also has Ownership Interest in SKS Ocular LLC.
    Neil M. Bressler, MD
    Disclosure: Dr. Bressler's institution receives Contracted Research funding from Bayer, Genentech/Roche, Novartis and Regeneron.
    Katherine Galluzzi, DO, CMD, FACOFP dist.
    Disclosure: Dr. Galluzzi has no relevant financial relationships to disclose.
    Planning Committee
    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
    Kelly Kraines of Med Learning Group has no relevant financial relationships to disclose.
    Christopher Cahill, of Med Learning Group has no relevant financial relationships to disclose.
    Joshua Kilbridge of Kilbridge Associates has no relevant financial relationships to disclose.

    Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
    This CME activity was planned and produced in accordance with the ACCME Essentials.
    For CME questions, please contact: Med Learning Group at info@medlearninggroup.com
    Contact this CME provider for privacy and confidentiality policy statement information at:
    Med Learning Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit.
    • You must score 65% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
    Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
    Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 18.0+ for Windows, Mac OS, or Linux 
    Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux   
    Safari 4.0+ for Mac OSX 10.5 and above
    Release Date: August 8, 2013
    Expiration Date: August 7, 2014
    MEDIUM: Internet
    This activity is sponsored by Med Learning group.                                  

    This activity is supported by an educational grant from Genentech.
    If you have any questions regarding this activity, send an email to info@medlearninggroup.com.
    This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields.  
    Copyright © 2013 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.